Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781583 · ClinicalTrials.gov registry record · NA
SmartHMD for Improved Mobility
A NA study of Mobility Limitation and Low Vision, sponsored by James Weiland.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03781583: Completed NA study of Mobility Limitation and Low Vision, sponsored by James Weiland.
NCT03781583 is a NA study of Mobility Limitation and Low Vision that has completed, run by James Weiland. The registered enrollment target is 21 participants, below the 255-participant average among 28 other Mobility Limitation trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03781583, a NA study of Mobility Limitation and Low Vision, has completed, sponsored by James Weiland.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The National Eye Institute estimated about 3 million people over age 40 in the US had low vision in 2010 and projects an increase to nearly 5 million in 2030 and 9 million in 2050. Current assistive technologies are a patchwork of mostly low-technology aids with limited capabilities that are often difficult to use, and are not widely adopted. This shortfall in capabilities of assistive technology often stems from lack of a user-centered design approach and is a critical barrier to improve the everyday activities of life (EDAL) and the quality of life (QOL) for individuals with low vision. An intuitive head mounted display (HMD) system on enhancing orientation and mobility (O\&M) and crosswalk navigation, could improve independence, potentially decrease falls, and improve EDAL and QOL. The central hypothesis is that an electronic navigation system incorporating computer vision will enhance O\&M for individuals with low vision. The goal is to develop and validate a smartHMD by incorporating advanced computer vision algorithms and flexible user interfaces that can be precisely tailored to an individual's O\&M need. This project will address the specific question of mobility while the subject crosses a street at a signaled crosswalk. This is a dangerous and difficult task for visually impaired patients and a significant barrier to independent mobility.
Primary Outcome
Duration from start of trial to subject completing their assigned task (seconds).
Conditions Studied
Interventions
- DEVICE SmartHMD version 1
- DEVICE SmartHMD version 2
- DEVICE SmartHMD version 3
- DEVICE SmartHMD version 4
Study Locations (1)
Michigan
- North Campus Research Complex - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-04-26 |
| Est. Completion | 2022-11-07 |
| Phase | NA |
What the finished NCT03781583 record still lists
NCT03781583 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 255-participant average among 28 other Mobility Limitation trials with a reported enrollment target (92% lower).
The record links to 5 conditions, with Mobility Limitation appearing as the primary indexed condition, and to 4 interventions - of which SmartHMD version 1 is the first listed.
NCT03781583 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03781583 about?
NCT03781583 is a clinical study titled "SmartHMD for Improved Mobility". The National Eye Institute estimated about 3 million people over age 40 in the US had low vision in 2010 and projects an increase to nearly 5 million in 2030 and 9 million in 2050. Current assistive technologies are a patchwork of mostly low-technology aids with limited capabilities that are often d...
What is the current status of trial NCT03781583?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2019-04-26. Estimated completion is 2022-11-07.
What conditions does trial NCT03781583 study?
This clinical trial studies the following conditions: Mobility Limitation, Low Vision, Visual Impairment, Orientation, Navigation, Spatial.
What interventions are being tested in trial NCT03781583?
The interventions under investigation include: SmartHMD version 1 (DEVICE), SmartHMD version 2 (DEVICE), SmartHMD version 3 (DEVICE), SmartHMD version 4 (DEVICE).
Who is sponsoring clinical trial NCT03781583?
This trial is sponsored by James Weiland, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03781583 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mobility Limitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03781583's enrollment target sits among peer trials
21 25th of 28 higher than 4 of 28 other Mobility Limitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mobility Limitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia
RECRUITING · NA
-
Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults
RECRUITING · NA
-
Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients
RECRUITING · NA
-
High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV
ACTIVE NOT RECRUITING · NA
-
Telehealth Based Intervention to Improve Functional Capacity in Survivors of Childhood Cancer With Significantly Limited Exercise Tolerance
ACTIVE NOT RECRUITING · NA
-
Randomized Clinical Trial to Improve Mobility After Hospitalization
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI